Dexamethasone Enhances Achilles Tendon Healing in an Animal Injury Model, and the Effects Are Dependent on Dose, Administration Time, and Mechanical Loading Stimulation

Franciele Dietrich-Zagonel,*† MSc, PhD, Per Aspenberg,‡ MD, Prof, and Pernilla Eliasson,¶ MSc, PhD

Investigation performed at Linköping University, Linköping, Sweden

Background: Corticosteroid treatments such as dexamethasone are commonly used to treat tendinopathy but with mixed outcomes. Although this treatment can cause tendon rupture, it can also stimulate the tendon to heal. However, the mechanisms behind corticosteroid treatment during tendon healing are yet to be understood.

Purpose: To comprehend when and how dexamethasone treatment can ameliorate injured tendons by using a rat model of Achilles tendon healing.

Study Design: Controlled laboratory study.

Methods: An overall 320 rats were used for a sequence of 6 experiments. We investigated whether the drug effect was time-, dose-, and load-dependent. Additionally, morphological data and drug administration routes were examined. Healing tendons were tested mechanically or used for histological examination 12 days after transection. Blood was collected for flow cytometry analysis in 1 experiment.

Results: We found that the circadian rhythm and drug injection timing influenced the treatment outcome. Dexamethasone treatment at the right time point (days 7-11) and dose (0.1 mg/kg) significantly improved the material properties of the healing tendon, while the adverse effects were reduced. Local dexamethasone treatment did not lead to increased peak stress, but it triggered systemic granulocytosis and lymphopenia. Mechanical loading (full or moderate) is essential for the positive effects of dexamethasone, as complete unloading leads to the absence of improvements.

Conclusion: We conclude that dexamethasone treatment to improve Achilles tendon healing is dose- and time-dependent, and positive effects are perceived even in a partly unloaded condition.

Clinical Relevance: These findings are promising from a clinical perspective, as the positive effect of this drug was seen even when given at lower doses and in a moderate loading condition, which better mimics the load level in patients with tendon ruptures.

Keywords: corticosteroids; repair; resolution; rat; calcaneal tendon; biomechanics

Corticosteroids are widely used in the clinic to treat chronic tendon disorders. However, this treatment might be detrimental because of adverse side effects and may even cause tendon ruptures. Corticosteroids can be administered as systemic or local treatment, and this might have diverse immunological effects and hence modulate tendon healing. Local injections are controversial and show negative and positive effects on intact and healing tendons. We previously showed in rats that systemic corticosteroid treatment during the early inflammatory phase (days 0-4) impaired tendon healing. In contrast, an improvement of the material properties of the tendon was seen when the drug was administered during the proliferative phase of healing (days 5-9). Nevertheless, when and how this drug should be administered for optimal healing needs to be better understood.

The Achilles tendon builds the connection between the calf muscles (gastrocnemius and soleus) and the calcaneal bone. This tendon is mainly formed by collagen and even though if it can stretch, injuries are common. Healing of tendon injuries is usually divided into 3 overlapping phases. In rats, the healing process occurs faster than in humans, and the exact days that each phase

The American Journal of Sports Medicine 1–11 DOI: 10.1177/03635465221077101 © 2022 The Author(s)
starts and finishes depend on many factors, such as the size of the injury. The inflammatory phase starts at the time of the injury and persists for some days, while the proliferative and remodeling phases endure for longer periods. After an injury, inflammation has to be resolved for regeneration to start. Anti-inflammatory drugs such as dexamethasone act through resolution of the inflammation. We hypothesized that delayed dexamethasone treatment would lead to faster resolution, earlier remodeling, and enhanced mechanical properties of the healing tendon.

Many factors are known to influence the tendon-healing process. The circadian rhythm has been reported to regulate collagen homeostasis in intact tendons. Although the circadian rhythm probably influences tendon healing, little is known about this. Changes in the microbiome have been reported to influence tendon healing as well as different immunomodulatory treatments, including platelet-rich plasma and corticosteroids. Moreover, there are interactions between the effect of loading and immunological changes during tendon healing. Different load magnitudes have been shown to activate distinct mechanisms and have diverse effects on the structural and material properties of the healing tendon. Full loading triggers a stronger proinflammatory response than moderate loading, possibly because of microdamage and infiltrating leukocytes. Despite this obvious effect on the inflammatory response, previous studies on the effect of dexamethasone on tendon healing have used full loading models, and different load levels might display distinct outcomes. Hence, a more comprehensive understanding is essential in terms of how this treatment interacts with the immune system and how it responds when having altered load magnitudes, especially because patients with tendon ruptures seldom have high-load magnitudes on their injured tendons.

Our study was based on a sequence of experiments. Every new finding led us to a new hypothesis and a new research question. The aim of this study was (1) to find the optimal administration time, route, and dose of dexamethasone for improving Achilles tendon healing and (2) to investigate if the positive effect of this treatment depends on the level of mechanical loading.

METHODS

Study Design

Specific pathogen–free female Sprague-Dawley rats were used (n = 320; Taconic Biosciences). The study was performed as a sequence of 6 experiments. Each group consisted of 10 randomly assigned rats (by lottery), except for the groups used for flow cytometric analysis and histological analysis (n = 6 in each group). All animals were euthanized 12 days postoperatively. Experiments were approved by the regional ethics committee for animal experiments in Linköping (15-15 and 1424).

Experiments 1-3. The aim of experiments 1, 2, and 3 was to study if different levels and injection time points for dexamethasone treatment resulted in diverse effects on tendon healing (Table 1). Dexamethasone (Dexaject; Dopharma Research BV) was given at a dose of 0.5 or 0.1 mg/kg for 5 or 2 consecutive days or as a single injection. Experiment 1 was unintentionally performed when the light cycle was reversed, and injections were performed at 11 AM. This experiment was repeated with injections at 7 AM because our positive control (dexamethasone; 0.5 mg/kg; given at days 5 to 9) had an unexpectedly small effect as compared with previous data. Experiments 2 and 3 were performed with a standard light cycle and injections at 3.30 PM. Saline solution 0.9% (B Braun Melsungen AG) was given to the control groups.

Experiment 4. The aim of experiment 4 was to compare systemic and local administration routes for dexamethasone. Dexamethasone was given as local (0.1 or 0.02 mg/kg) or systemic (0.1 mg/kg) injections for 5 consecutive days (days 7-11). Local injections were performed with an insulin syringe. Saline was also given as local injections.

Experiment 5. Experiments 1 to 3 showed that high doses of dexamethasone led to reduced muscle weight. As such, the aim of experiment 5 was to investigate if the effect of dexamethasone derived from a delayed reduction in loading (attributed to less muscle mass) or from a drug-specific effect. One group was therefore given injections of botulinum toxin (Botox) in the calf muscle at day 7 to achieve a delayed reduction in loading. This group was compared with dexamethasone treatment and saline.

Experiment 6. The aim of experiment 6 was to investigate if the positive effect of dexamethasone treatment (0.1 mg/kg) depends on the level of tensile loading. Dexamethasone or saline was administered to rats with full loading (free cage activity), moderate loading (Botox injections in the calf muscle), or complete unloading (Botox injections in the calf muscle and a steel orthosis boot) for 5 consecutive days.

Standard Procedures

Animals. Female rats weighing on average 213 g (SD, 18 g) were placed in pairs into acrylic cages containing wooden pegs, shredded paper, and hiding places. The cages were individually ventilated, and the room was kept at a controlled temperature of 22°C, humidity of 55%, and...
a 12-hour light-dark cycle. A standard light cycle means light from 7 AM to 7 PM. Food and water were given ad libitum.

Model Used to Reduce Loading. Botox injections were used to reduce tensile loading (moderate loading) (Table 1, Figure 1). Botox (Allergan) injections were performed under anesthesia with isoflurane gas (Forene; Abbot Scandinavia). The gastrocnemius lateralis, gastrocnemius medialis, and soleus muscles in the right leg were injected with 1 U of Botox per muscle, for a total of 3 U and 0.06 mL per animal. A steel orthosis boot (Prodelox) was used in the unloaded group after tendon surgery to prevent joint movement and passive loading, accomplishing complete unloading. Botox effectiveness was visually confirmed before surgery.

Surgical Procedure. Complete tendon transection was achieved under general anesthesia with isoflurane gas.
(Forene; Abbot Scandinavia) under aseptic conditions. Subcutaneous antibiotic (25 mg/kg, oxytetracycline; Emegy- 
cycin [Intervet]) was given once preoperatively, and sub- 
cutaneous analgesia (0.045 mg/kg, buprenorphine; Temgesic [Indivior Europe Limited]) was given pre- and 
postoperatively. During surgery, rats were placed in 
a prone position. A minor skin incision was made lateral 
to the right Achilles tendon to expose the tendon complex. The plantaris tendon was removed and the Achilles tendon 
was completely transected with a single transversal cut in 
the midtendon portion. The tendon was left to heal nonsu-
tured, and the skin was closed.

Mechanical Testing. Ten rats in each group were eutha-
nized with carbon dioxide 12 days postsurgery, and the 
tendon was harvested in a standardized way with the cal-
caneal bone and calf muscle. The transverse area and gap 
length were measured by a caliper. These measurements 
were performed twice on a subset of the tendons (n = 50) 
by the same investigator (F.D.Z.) (P < .001, R² = 0.96, for 
transverse area; P < .001, R² = 0.94, for gap length). The 
samples were thereafter weighted before the majority of 
the muscle was scraped out. The tendon was mounted in 
the materials testing machine (100R; DDL Inc) and pulled 
at a constant speed of 0.1 mm/s until failure. Peak force at 
failure (N) and energy uptake until failure (N/mm) were 
recorded by the software (MtestW Version 5.1.0; ADMET). 
The investigator marked a linear portion of the curve for 
automated stiffness calculation (N/mm). Peak stress 
(MPa; peak force/transverse area) and estimation of elastic 
modulus (MPa; stiffness × gap length/transverse area) 
were calculated assuming an elliptical cylindrical shape 
and homogeneous mechanical properties. The method 
used in this study has been described previously.17 All sur-
gical procedures and mechanical tests were performed 
blinded from treatment by giving the tendons a random 
identification number before they were measured and 
tested.

Flow Cytometry. Eighteen rats were used for immune 
cell characterization by flow cytometric analyses after local 
and systemic dexamethasone treatment or saline. The 
analysis was performed to investigate if local injections 
gave a systemic response. Rats were anesthetized with iso-
flurane gas. Blood was collected by a cardiac puncture and 
immediately placed into tubes containing EDTA (BD Vacu-
tainer) and kept on ice. To separate the mononuclear cells, 
the blood was carefully layered on Histopaque-1119 (Sigma-
Aldrich) and centrifuged at room temperature (700g for 45 
min), followed by buffy coat collection and addition of sup-
port buffer (RPMI 1640 without l-glutamine and phenol 
red, 4% inactivated fetal bovine serum, 5 mM EDTA, and 
25 mM HEPES). The suspension was washed twice at 
600g for 6 minutes, and 1 to 3 million cells were collected 
in Cell Staining Buffer (Biolegend) and incubated 20 
minutes while protected from the light and on ice with anti-
bodies (Appendix Table A1, available in the online version of 
this article). For live/dead discrimination, Zombie Violet 
(Biolegend) was added. Cells were fixed in 2% paraformal-
dehyde at room temperature (Biolegend) and washed twice 
with Cell Staining Buffer. Cells from a control rat were used 
for fluorescence minus one gating. To sustain blinding, the 
operator (F.D.Z.) did not know which rat this was. FACS 
Aria III (BD Biosciences) was used in this study, and 
Cytometer Setup and Tracking Beads (BD Biosciences) 
ensured the stability of the cytometer. Compensation 
was performed with the same antibodies as in the experiment, 
and the gatings of discrete antigens were set on population 
morphology. In all samples, initial gating was performed on 
singlet cells, scatter parameters, and live cells to define sin-
gle living leukocytes. Gating was performed in FlowJo Ver-
sion 10.0.7 (Treestar). This method has been described in 
detail previously.4

Histological Examination. Twelve rats were used for 
histological imaging with normal hematoxylin and eosin 
staining on saline- and dexamethasone-treated tendons. 
Rats were anesthetized with isoflurane gas at 12 days post-
surgery. Tendons were harvested and fixed in 4% phos-
phate-buffered formaldehyde overnight, followed by 
dehydration and paraffin embedding. Longitudinal sec-
tions (7 μM) were made, and hematoxylin and eosin stain-
ing was performed. Images were captured using a light
microscope (Olympus BX51) with an attached camera (Olympus DP73) and the software cellSens Entry (Version 1.8.1; Olympus Corporation). Three objective lenses were used: 4×/0.13, 10×/0.30, and 20×/0.50 (UPlanFL; Olympus).

Exclusion. One rat in the dexamethasone 0.1-mg/kg group in experiment 1 was excluded from the mechanical analysis because of rupture by the distal clamp. One rat in the dexamethasone ×1 group in experiment 3 was excluded from analysis owing to rupture by the proximal clamp. Blood collection for flow cytometry analysis in experiment 4 failed in 4 rats in the local treatment group. Two rats were also excluded from the mechanical analysis in experiment 4, 1 in the saline group and 1 in the dexamethasone systemic group, owing to rupture by the clamp.

Statistical Analysis

The results were analyzed using SPSS Version 21 (IBM), and graphs were created using Prism Version 9 (GraphPad). The predefined primary variable was always peak stress. Experiments 1 to 4 were analyzed by independent-samples t tests. Experiment 5 was analyzed with 1-way analysis of variance, followed by Bonferroni post hoc for multiple-comparison analyses, and experiment 6 was analyzed by a 2-way analysis of variance. Independent t tests comparing the treated and saline groups were performed within each loading condition.

RESULTS

Experiment 1

The positive effect of dexamethasone is dependent on the administration time point during the day, possibly through the circadian rhythm.

Experiment 1 showed that dexamethasone treatment (0.5 mg/kg) increased the peak stress of the tendon by 27% (P = .008) and elastic modulus by 70% (P < .001) (Appendix Table A2, available online). The effect on peak stress was, however, not as powerful as previously observed6 (Figure 2). The experiment was repeated with similar results. The discrepancy in the magnitude of increase in peak stress between experiment 1 and previous data was then traced to the reversed light cycle, as all previous studies had been performed with a standard light cycle. Experiment 1 also showed that dexamethasone treatment led to an increased gap length and a smaller transverse area as compared with saline (P < .05 for both).

Experiment 2

Treatment delay into the later healing phase gives further improvement of the structural and material properties of the tendon.

Experiment 2 showed that dexamethasone treatment, irrespective of treatment initiation, led to increased material properties, with an increase in peak stress and estimate of elastic modulus (P < .005 for all groups vs saline). The peak stress was 19% higher in the dexamethasone days 7-11 group as compared with our positive control (dexamethasone, days 5-9), although this difference was not statistically significant (Table 2, Figure 3). However, peak force was significantly higher in the dexamethasone days 7-11 group versus the saline group and dexamethasone days 5-9 group. Stiffness was higher in the dexamethasone days 6-10 group and days 7-11 group than in the saline group. Experiment 2 also showed that 0.5 mg/kg of dexamethasone resulted in adverse effects, as measured by a smaller transverse area and calf muscle atrophy (P < .05 for both). The gap length in the dexamethasone days 7-11 group was similar to that in the saline group but in contrast to the dexamethasone days 5-9 group.

Experiment 3

When using the optimal time point (days 7-11), dexamethasone dose can be reduced 5-fold and still enhance tendon healing.

Experiment 3 showed that dexamethasone treatment increased peak stress in all groups as compared with saline. The most pronounced effect was seen with 5 consecutive
injections of dose 0.5 mg/kg (95% increase) or 0.1 mg/kg (77% increase), with no statistical difference between them ($P = .29$) (Table 3, Figure 3). Elastic modulus was increased by 169% and 142%, respectively. The transverse area was reduced after 5 injections (irrespective of the dose) or 2 injections but not after a single injection. Muscle atrophy was seen in all treated groups but less pronounced in the groups with 0.1 mg/kg or a reduced number of injections. Gap length was increased in all dexamethasone-treated tendons as compared with saline, while stiffness was increased after 5 injections, irrespective of the dose.

### Experiment 4

The positive dexamethasone outcomes on healing tendons are reliant on the route of administration, although local treatment still triggers granulocytosis and T-cell reduction. Experiment 4 showed that peak stress did not differ between the groups with local dexamethasone treatment and local saline treatment (Table 4, Figure 4A).

Dexamethasone-treated tendons (0.1 mg/kg) became slightly stiffer when compared with saline. Flow cytometric analysis of the peripheral blood showed a systemic reaction to the dexamethasone despite local treatment. Dexamethasone-treated animals, local and systemic, showed signs of granulocytosis, with a specific increase in the CD11b population as well as lymphopenia (Figure 4B; Appendix Table A4, available online). The effect on granulocytes, CD11b subpopulation, and lymphocytes was surprisingly somewhat more pronounced in the locally treated animals in relation to the systemic ones ($P < .05$). Dexamethasone, independent of the administration route, also induced a small reduction in CD8$^+$ and CD4$^+$ T-cell populations ($P < .05$).

### Experiment 5

Reduced loading by paralyzing the calf muscle does not mimic the dexamethasone effect.

To differentiate between reduced loading attributed to muscle atrophy and the treatment effect, a comparison...
was done between dexamethasone treatment and delayed load reduction by Botox injections in experiment 5. Dexamethasone treatment resulted in improved tendon material properties, while delayed load reduction reduced all analyzed tendon mechanical parameters (Appendix Table A3, available online).

Experiment 6

The effect of dexamethasone on tendon mechanical properties differs by load magnitude. Experiment 6 showed no significant interaction between loading and dexamethasone treatment for our predefined variable peak stress ($P = .09$) (Table 5). Dexamethasone treatment had positive effects in all loading conditions, although the effect was more pronounced with increased loading. Dexamethasone treatment increased peak stress by 50% to 60% when compared with saline in fully and moderately loaded groups but not in the unloaded group (Figure 5). Stiffness was increased in the moderately loaded group by approximately 50% ($P < .04$). Moreover, the transverse area tended to be smaller in the fully loaded group ($P = .053$) but not in the other groups. Muscle weight was significantly reduced by dexamethasone treatment in the unloaded group, although not in the other loading conditions. Hematoxylin and eosin staining of fully loaded rats (saline and dexamethasone) revealed no distinct difference between the groups with regard to cellularity or matrix structure (Figure 6).

DISCUSSION

With this study, not only did we confirm that dexamethasone treatment can ameliorate Achilles tendon healing, but we also showed a more pronounced improvement in the material properties when treatment was protruded into the proliferative/early remodeling phase and that the positive effect remained when the daily loading was reduced. Furthermore, despite a significant reduction in the dexamethasone dose, the beneficial effects of the drug were still observed, making our findings more relevant in a clinical context.

**TABLE 3**

| Material properties | Saline | Dexa × 5, 0.5 mg/kg | $P$ Value | % | Dexa × 5, 0.1 mg/kg | $P$ Value | % | Dexa × 1, 0.5 mg/kg | $P$ Value | % | Dexa × 2, 0.5 mg/kg | $P$ Value | % |
|---------------------|--------|---------------------|-----------|---|---------------------|-----------|---|---------------------|-----------|---|---------------------|-----------|---|
| Peak stress, MPa    | 2.2 (0.5) | 4.3 (0.6)       | .001     | 95 | 3.9 (0.7)        | .001     | 77 | 3.1 (0.7)          | .007     | 41 | 3.2 (0.4)          | .001     | 45 |
| Est. elastic modulus, MPa | 2.6 (0.8) | 7.0 (1.7)       | .001     | 169 | 6.3 (1.6)        | .001     | 142 | 4.3 (1.4)          | .005     | 65 | 4.4 (1.2)          | .001     | 69 |

**TABLE 4**

| Material properties | Saline | Dexa, 0.1 mg/kg | $P$ Value | % | Dexa, 0.02 mg/kg | $P$ Value | % |
|---------------------|--------|-----------------|-----------|---|-----------------|-----------|---|
| Peak stress, MPa    | 2.6 (1.0) | 3.2 (0.9)       | .146     | 23 | 2.7 (0.7)       | .787     | 4 |
| Est. elastic modulus, MPa | 2.8 (1.3) | 3.5 (1.0)       | .192     | 25 | 2.8 (1.2)       | .972     | 0 |

$^a$Values are presented as mean (SD). Percentage was calculated in relation to the saline group ($n = 10$ in each group except for dexamethasone (Dexa) $\times 1$, $n = 9$). All injections were given from day 7 to day 11. Bold indicates significant difference vs saline.

$^b$Significant difference vs 5 injections with Dexa, 0.5 mg/kg.

$^c$Values are presented as mean (SD). Percentage was calculated in relation of the saline group ($n = 9$ for saline and dexamethasone (Dexa), $n = 10$, Dexa, 0.02 mg/kg). Bold indicates significant difference vs saline.
perspective. Additionally, dexamethasone, independent of the administration route, led to alterations in the immune system on a systemic level. Moreover, the positive effects of dexamethasone seem to be affected by the circadian rhythm.

The circadian rhythm is important for maintaining intact tendon tissue function and organization, and it influences collagen homeostasis.8 We observed that our initial experiments led to unexpectedly low improvement in our positive control. We were able to trace this back to the change in light cycle in the animal facility. The altered light cycle led to changes in the timing of the injections, from evening to morning. Previous studies have shown that disruptions in the circadian rhythm can lead to irregular fibril structures and a reduction in maximum load and elastic modulus in intact Achilles tendons.8 Furthermore, rat cornea mitotic activity in response to dexamethasone treatment has been reported to differ according to the time of the day when the drug is administered.7 Previous studies on healing tendons and dexamethasone treatment were all performed with injections done a few hours before the rats woke up.6,17 However, when the light cycle was altered to a reversed light cycle, injections were instead given in the morning when rats were starting to be active.18 In addition, although the rats in our study had been acclimatized for 2 weeks, changes in the natural cycle

### Figure 4
Mechanical and flow cytometry data after local and systemic dexamethasone (Dexa) treatment for 5 consecutive days. (A) Peak stress after local treatment on days 7 to 11 with saline (n = 9) or Dexa (0.1 mg/kg, n = 9, dotted boxes; 0.02 mg/kg, n = 10, striped boxes). Saline, n = 9; Dexa, n = 9 (0.1 mg/kg) and n = 10 (0.02 mg/kg). Line, median; box, interquartile range; error bars, minimum and maximum. (B) Flow cytometry data from animals receiving Dexa (systemic or local injections) or saline (systemic) on days 7 to 11. Saline, n = 6; systemic Dexa, n = 6; local Dexa, n = 2. Gran, granulocytes; lymph, lymphocytes. *Significant difference vs saline. ▲Significant difference vs Dexa systemic. Bar, mean; error bars, SD.

### TABLE 5
Mechanical Results From Experiment 6

| Material properties | Full Loading | Moderate Loading | Unloading | 2-Way ANOVA, P Value |
|---------------------|-------------|-----------------|-----------|---------------------|
| Peak stress, MPa    | 2.6 (0.7)   | 4.0 (1.2)       | < .001    | .004                |
| Est. elastic modulus, MPa | 3.9 (1.3) | 5.9 (2.6)       | < .001    | .005                |
| Structural properties | Transverse area, mm² | 12 (3.1) | 9.2 (2.0) | .053                 |
| Gap length, mm      | 8.3 (1.0)   | 7.9 (1.6)       | .046      | .005                |
| Peak force, N       | 29 (9.4)    | 35 (7.2)        | .069      | .017                |
| Stiffness, N/mm     | 5.1 (1.5)   | 6.4 (1.4)       | .040      | .002                |
| Energy uptake, N/mm | 69 (20)     | 71 (15)         | .099      | .004                |
| Sample weight, g    | 2.1 (0.3)   | 1.8 (0.2)       | < .001    | .004                |
| Muscle weight, g     | 1.5 (0.2)   | 1.4 (0.2)       | < .001    | .004                |

*Values are presented as mean (SD). Percentage was calculated in relation to the saline group (n = 10 in each group except for the muscle weight measurement for the saline unloading group, n = 8). Bold indicates significant difference vs saline. ANOVA, analysis of variance; Dexa, dexamethasone.
can lead to stress, elevated cortisol levels, and altered wound healing. Earlier research has shown that higher cortisol levels can delay healing processes by modified cytokine production, leading to ongoing inflammation instead of proceeding into the proliferative/remodeling phase.

With this in mind, a normal light cycle with a standardized injection time was used in the remaining experiments (2-6). It is believed that inflammation should be resolved before tissue regeneration can start, and dexamethasone treatment for a short period may promote this. As seen previously, dexamethasone treatment during the proliferative phase (days 5-9) improves the material and structural properties of the healing tendon. Despite improved material properties in the tendons, we sometimes observed that treated tendons became elongated. Within this study, when the treatment was delayed further into the proliferative phase or perhaps into the early remodeling phase at days 7 to 11, more pronounced improvement of the material properties was seen. This delay in treatment also led to less tendon elongation when compared with our positive control. The presence of tendon elongation and fibrotic tissue after a tendon injury is a common clinical challenge. Better clinical

**Figure 5.** Material properties from experiment 6. (A) Peak stress. (B) Estimation of elastic modulus. All groups received daily systemic injections of saline or dexamethasone ([Dexa] 0.1 mg/kg; days 7-11). All groups, n = 10. *Significant difference vs saline. Line, median; box, interquartile range; error bars, minimum and maximum.

**Figure 6.** Hematoxylin and eosin staining of tendons from fully loaded rats treated with (A-C) saline or (D-F) 0.1 mg/kg of dexamethasone on days 7 to 11. Magnification for images: (A, D) 40×, (B, E) 100×, (E, F) 200×.
Dexamethasone treatment had more pronounced effects in fully or moderately loaded rats than unloaded ones. The effect in fully loaded rats corresponds to that found in previous studies. However, full loading does not relate well to humans with an Achilles tendon injury; thus, moderate loading is more relevant. Full loading and moderate loading have been shown to activate somewhat different mechanisms after a tendon rupture. Full loading acts through mechanotransduction and microdamage and leads to an increased proinflammatory response, while moderate loading acts primarily through mechanotransduction. As a positive effect of dexamethasone also was observed with reduced loading, this might indicate that dexamethasone improves tendon healing in more ways than an immunomodulatory effect, possibly through a direct effect on tendon cells. Notably, moderate loading had no significant effect on muscle weight, as seen with full loading and unloading. The exact mechanism of corticosteroids during tendon healing is not yet clear, although one study did show a reduced number of CD8a+ cells in dexamethasone-treated tendons and improved collagen alignment.

We observed that total granulocytes and the CD11b population increased, while CD4+ and CD8+ T cells decreased, after systemic and local dexamethasone treatment. Granulocytosis and lymphopenia are known effects of corticosteroids, and the results in the locally treated group indicate that the systemic effect cannot be avoided even with local injections. Local corticosteroid injections have been reported to cause detrimental effects on intact and healing tendons. Although we did not observe any adverse effects by local treatment, beneficial effects were absent. Overall, positive mechanical outcomes of dexamethasone on healing Achilles tendons seem to be reliant on the route of administration.

This study is not without limitations. We used only female rats, as they grow more slowly and are more reproducible in the mechanical testing. Furthermore, the same investigator performed all surgical procedures, injections, and mechanical tests. This can be considered a limitation or an advantage. The results in the experiments have probably less variation, but this can also include a bias. However, all surgery and mechanical testing were performed with the investigator blinded from treatment.

To the best of our knowledge, this study is the first to demonstrate that the beneficial effects of dexamethasone on tendon healing are dependent on the timing of treatment, route of drug administration, drug dose, and degree of loading. Additional studies on the mechanisms behind the effect of dexamethasone are desirable for further conclusions, as the treatment might act via systemic effects and local effects specific to the tendon cell and matrix. Moreover, the positive effects of corticosteroid treatment, without adverse effects, are more pronounced during the late proliferative phase or early remodeling phase (by daily systemic injections from days 7 to 11) and using the 0.1 mg/kg dose.

CONCLUSION

Dexamethasone treatment can improve tendon healing. The effect of the treatment is dependent on the dose and timing of drug administration. We here suggest that the drug ought to be administered during the proliferative or early remodeling phase for an optimal outcome. The therapeutic effect of dexamethasone is apparent even with moderate loading, which relates more to the human situation, where full loading is avoided. Thus, the findings indicate a promising prospect for improving the material properties of the healing tendon with the use of delayed dexamethasone treatment.

ACKNOWLEDGMENT

The authors thank Anders Delleskog, Alexandra Mårbring, Björn Wolbert, Emelie Lindblom, Emelie Jansson, Malin Hammerman, and Magnus Bernhardsson for their assistance during surgery. We also thank Love Tätting for double-checking the flow cytometry data accuracy.

ORCID iDs

Franciele Dietrich-Zagonel https://orcid.org/0000-0003-4871-8268
Pernilla Eliasson https://orcid.org/0000-0001-6718-034X
REFERENCES

1. Andreakos E, Papadaki M, Serhan CN. Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19. Allergy. 2021;76(3):626-628.

2. Aspenberg P. Stimulation of tendon repair: mechanical loading, GDFs and platelets: a mini-review. Int Orthop. 2007;31(6):783-789.

3. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009;23(11):3649-3658.

4. Bernhardsson M, Dietrich-Zagonel F, Tatting L, Eliasson P, Aspenberg P. Depletion of cytotoxic (CD8+) T cells impairs implant fixation in rat cancellous bone. J Orthop Res. 2019;37(4):805-811.

5. Blomgran P, Blomgran R, Ernerudh J, Aspenberg P. A possible link between loading, inflammation and healing: immune cell populations during tendon healing in the rat. Sci Rep. 2016;6:29824.

6. Blomgran P, Hammerman M, Aspenberg P. Systemic corticosteroids improve tendon healing when given after the early inflammatory phase. Sci Rep. 2017;7(1):12468.

7. Cardoso SS, Sowell JG, Goodrum PJ, Fustc G. Effect of dexamethasone upon circadian mitotic rhythm in rat cornea. Proc Soc Exp Biol Med. 1972;140(4):1235-1239.

8. Chang J, Garva R, Pickard A, Yeung CC, Mallikarjun V. Circadian phase. Improvement of dexamethasone side effects in rats. Front Pharmacol. 2016;7:230.

9. Christian LM, Graham JE, Padgett DA, Glaser R, Kiecolt-Glaser JK. Stress and wound healing. Neuroimmunomodulation. 2006;13(5-6):337-346.

10. Claman MN. How corticosteroids work. J Allergy Clin Immunol. 1975;55(3):145-151.

11. Costa ML, MacMillan K, Halliday D, et al. Randomised controlled trials of immediate weight-bearing mobilisation for rupture of the tendon Achill. J Bone Joint Surg Br. 2006;88(1):69-77.

12. Dayton P. Anatomic, vascular, and mechanical overview of the Achilles tendon. Clin Podiatr Med Surg. 2017;34(2):107-113.

13. Dean BJ, Carr AJ. The effects of glucocorticoid on tendon and tendon derived cells. Adv Exp Med Biol. 2016;920:239-246.

14. Dietrich F, Duré LG, Klein PC, et al. Platelet-rich fibrin promotes an accelerated healing of Achilles tendon when compared to platelet-rich plasma in rat. World J Plast Surg. 2015;4(2):101-109.

15. Dietrich F, Hammerman M, Blomgran P, et al. Effect of platelet-rich plasma on rat Achilles tendon healing is related to microbiota. Acta Orthop. 2017;88(4):416-421.

16. Dietrich-Zagonel F, Hammerman M, Eliasson P, Aspenberg P. Response to mechanical loading in rat Achilles tendon healing is influenced by the microbiome. PLoS One. 2020;15(3):e0229908.

17. Dietrich-Zagonel F, Hammerman M, Tatting L, et al. Stimulation of tendon healing with delayed dexamethasone treatment is modified by the microbiome. Am J Sports Med. 2018;46(13):3281-3287.

18. Dudek M, Meng QJ. Running on time: the role of circadian clocks in rat Achilles tendon healing. PLoS One. 2015;10(7):e0131187.

19. Ebercht M, Hextall J, Kirtley LG, Taylor A, Dyson M, Weinman J. Perioperative corticosteroid use in hip arthroplasty surgery: a prospective study. J Bone Joint Surg Br. 2020;92(3):364-369.

20. Eliasson P, Andersson T, Aspenberg P. Rat Achilles tendon healing: mechanical loading and gene expression. J Appl Physiol (1985). 2009;107(2):399-407.

21. Galatz LM, Gerstenfeld L, Heber-Katz E, Rodeo SA. Tendon regeneration and scar formation: the concept of scarless healing. J Orthop Res. 2015;33(6):823-831.

22. Hammerman M, Blomgran P. Different gene response to mechanical loading during early and late phases of rat Achilles tendon healing. J Appl Physiol (1985). 2017;123(4):800-815.

23. Hammerman M, Dietrich-Zagonel F, Blomgran P, Eliasson P, Aspenberg P. Different mechanisms activated by mild versus strong loading in rat Achilles tendon healing. PLoS One. 2018;13(7):e0202111.

24. Hansen M. Female hormones: do they influence muscle and tendon protein metabolism? Proc Nutr Soc. 2018;77(1):32-41.

25. Hansen M, Kjaer M. Influence of sex and estrogen on musculoskeletal tissue turnover at rest and after exercise. Exerc Sport Sci Rev. 2014;42(4):183-192.

26. Jahng JW, Kim NY, Ryu V, et al. Dexamethasone reduces food intake, weight gain and the hypothalamic S-HT concentration and increases plasma leptin in rats. Eur J Pharmacol. 2008;581(1-2):64-70.

27. Kangas J, Pajala A, Ohtonen P, Leppilaiti J. Achilles tendon elongation after rupture repair: a randomized comparison of 2 postoperative regimes. Am J Sports Med. 2007;35(1):59-64.

28. Kapetanos G. The effect of the local corticosteroids on the healing and biomechanical properties of the partially injured tendon. Clin Orthop Relat Res. 1982;163:170-179.

29. Knobloch K. Drug-induced tendon disorders. Adv Exp Med Biol. 2016;920:229-238.

30. Lin TW, Cardenas L, Soslowsky LJ. Biomechanics of tendon injury and repair. J Biomech. 2004;37(6):865-877.

31. Mahler F, Fritschy D. Partial and complete ruptures of the Achilles tendon and local corticosteroid injections. Br J Sports Med. 1992;26(1):7-14.

32. Malkawi AK, Alzoubi KH, Jacob M, et al. Metabolomics based profiling of dexamethasone side effects in rats. Front Pharmacol. 2018;9:46.

33. McEwen BS, De Kloet ER, Rostene W. Adrenal steroid receptors and actions in the nervous system. Physiol Rev. 1986;66(4):1121-1188.

34. Nakagawa M, Terashima T, D’Yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation. 1998;98(21):2307-2313.

35. Oxlund H. The influence of a local injection of cortisol on the mechanical properties of tendons and ligaments and the indirect effect on skin. Acta Orthop Scand. 1980;51(2):231-238.

36. Paavola M, Kunnus P, Järvinen TA, Järvinen TL, Józsa L, Järvinen M. Treatment of tendon disorders: is there a role for corticosteroid injection? Foot Ankle Clin. 2002;7(3):501-513.

37. Sapolsky RM, Romero LM, Muncik AL. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21(1):55-89.

38. Schepull T, Aspenberg P. Early controlled tension improves the material properties of healing human achilles tendons after ruptures: a randomized trial. Am J Sports Med. 2013;41(11):2550-2557.

39. Schepull T, Kivist J, Andersson C, Aspenberg P. Mechanical properties during healing of Achilles tendon ruptures to predict final outcome: a pilot Roentgen stereophotogrammetric analysis in 10 patients. BMC Musculoskelet Disord. 2007;8:116.

40. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6(12):1191-1197.

41. Speed CA. Fortnightly review: corticosteroid injections in tendon lesions. BMJ. 2001;323(7309):382-386.

42. Tatar H, Kosay C, Baran O, Ozcan O, Ozer E. Deleterious effects of local corticosteroid injections on the Achilles tendons of rats. Arch Orthop Trauma Surg. 2001;121(6):333-337.

43. Thomopoulos S, Parks WC, Rifkin DB, Derwin KA. Mechanisms of tendon injury and repair. J Orthop Res. 2015;33(6):832-839.

44. Tonolo G, Fraser R, Connell JM, Kenyon CJ. Chronic low-dose infusions of dexamethasone in rats: effects on blood pressure, body weight and plasma atriuretic peptide. J Hypertens. 1988;6(1):25-31.

45. Vago JP, Tavares LP, Garcia CC, et al. The role and effects of glucocorticoid-induced leucine zipper in the context of inflammation resorption. J Immunol. 2015;194(10):4940-4950.